Swiss healthcare company Galderma has announced the phase 2 clinical trial results for its liquid formulation of investigational botulinum toxin, QM1114. The study—conducted as multi-center, randomized, double-blind and placebo-controlled—successfully showcased the safety and efficacy of botulinum toxin type A, according to the company.
“Toxin treatment-naive subjects aged ≥18 years with moderate-to-very severe GLs [glabellar lines] at maximum frown and at least mild GLs at rest were eligible for this multi-centre, double-blind 6-month Phase II study,” according to the abstract from the oral presentation on the subject at the 24th World Congress of Dermatology, Milan.
Read more at Dermatology Times >>